How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: GABRB3

    Description: "gamma-aminobutyric acid (GABA) A receptor, beta 3"

    Entrez Gene ID: 2562

    SwissProt Acc Number: P28472

    RefSeq: NM_000814

    It was supported literatures to be a novel CHD related gene:

    ..we found significant evidence for linkage (LOD = 3.88) of ln TG levels to a genetic location between the markers GABRB3 and D15S165 on chromosome 15q...

    From PMID: 10729112, in Journal Am J Hum Genet , 2000


    References

    There were 1 potential papers with GABRB3 and CHD.

    PMIDTitleJournalsDetails
    10729112 A major susceptibility locus influencing plasma triglyceride concentrations is located on chromosome 15q in Mexican Americans.American journal of human geneticsMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 8 unique genes interacted with GABRB3. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    AKAP5 Reconstituted Complex12595241|12595241 No
    PRKCA Reconstituted Complex12595241 CHD related
    PRKACA Reconstituted Complex12595241 CHD related
    UBC Affinity Capture-Western18467327 No
    PPP2CA in vitro14724252 CHD related
    UBQLN1 Affinity Capture-Western11528422|11528422 No
    GNB2L1 in vitro14724252 No
    ARFGEF2 in vitro;in vivo;yeast 2-hybrid15198677 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00186Lorazepam"For the management of anxiety disorders, and for treatment of status epilepticus."N05BA06
    illicit;approvedDB00189Ethchlorvynol"Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents."N05CM08
    approvedDB00231TemazepamFor the short-term treatment of insomnia (generally 7-10 days).N05CD07
    illicit;approvedDB00349ClobazamFor treatment and management of epilepsy and anxiety disorder.N05BA09
    illicit;approvedDB00404Alprazolam"For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia."N05BA12
    illicit;approvedDB00475Chlordiazepoxide"For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety."N05BA02
    approvedDB00546AdinazolamFor the treatment of anxiety and status epilepticus.N05BA07
    approvedDB00592Piperazine"Used as alternative treatment for ascariasis caused by <i>Ascaris lumbricoides</i> (roundworm) and enterobiasis (oxyuriasis) caused by <i>Enterobius vermicularis</i> (pinworm). It is also used to treat partial intestinal obstruction by the common roundworm, a condition primarily occurring in children."P02CB01;R03DA09
    approvedDB00602Ivermectin"For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite <i>Strongyloides stercoralis</i>. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite <i>Onchocerca volvulus</i>. Can be used to treat scabies caused by <i>Sarcoptes scabiei</i>."P02CF01
    illicit;approvedDB00628ClorazepateFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.N05BA05
    illicit;approvedDB00683MidazolamFor use as a sedative perioperatively.N05CD08
    illicit;approvedDB00690FlurazepamFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habitsN05CD01
    illicit;approvedDB00801Halazepam"Used to relieve anxiety, nervousness, and tension associated with anxiety disorders."N05BA13
    approvedDB00818PropofolUsed for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. N01AX10
    illicit;approvedDB00829Diazepam"Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome."N05BA01;N05BA17
    approvedDB00842OxazepamFor the treatment of anxiety disorders and alcohol withdrawal. N05BA04
    illicit;approved;withdrawnDB00897TriazolamFor the short-term treatment of insomnia.N05CD05
    illicit;approvedDB01068Clonazepam"Used as an anticonvulsant in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures."N03AE01
    illicit;approvedDB01215Estazolam"For the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings."N05CD04
    illicit;approvedDB01558Bromazepam"For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal."N05BA08
    illicit;approvedDB01559ClotiazepamFor the treatment of anxiety disorders.
    illicit;approvedDB01567FludiazepamUsed for the short-term treatment of anxiety disorders.N05BA17
    illicit;approvedDB01588PrazepamFor the treatment of anxiety disorders.N05BA11
    illicit;approvedDB01589QuazepamUsed to treat insomnia.N05CD10
    approvedDB01594CinolazepamFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.N05CD13
    approvedDB01595Nitrazepam"Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening."N05CD03;N05CD02
    approvedDB06716FospropofolUsed for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.